Findings

What do systematic reviews say?

9 questions · 9 findings · 1 reviews · Colorectal

No studies found 2 · 22.2%GRADE not reported 0 · 0%Very low 1 · 11.1%Low 5 · 55.6%Moderate 1 · 11.1%High 0 · 0%

Grade 3 to 4 diarrhoea · people with metastatic colorectal cancer ‐ KRAS exon 2 MT

The intervention may leads to higher grade 3 to 4 diarrhoea (low certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
OR 1.45 [1.01, 2.11]
5 studies · 1635 participants
Low

Grade 3 to 4 diarrhoea · people with metastatic colorectal cancer ‐ extended RAS WT

The review found no eligible studies for this question.

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Grade 3 to 4 diarrhoea · people with metastatic colorectal cancer ‐ extended RAS MT

The review found no eligible studies for this question.

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Grade 3 to 4 diarrhoea · people with metastatic colorectal cancer, not selected by KRAS status

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1341 participants
Low

Grade 3 to 4 diarrhoea · people with metastatic colorectal cancer

It is very uncertain whether the intervention changes grade 3 to 4 diarrhoea (very low certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
OR 1.06 [0.67, 1.67]
2 studies · 1673 participants
Very low

Grade 3 to 4 diarrhoea · people with metastatic colorectal cancer ‐ KRAS exon 2 WT

The intervention probably leads to higher grade 3 to 4 diarrhoea (moderate certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
OR 1.84 [1.47, 2.32]
7 studies · 2909 participants
Moderate

Grade 3 to 4 diarrhoea · people with metastatic colorectal cancer, not selected by KRAS status

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 1651 participants
Low

Grade 3 to 4 diarrhoea · people with metastatic colorectal cancer, not selected by KRAS status

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 181 participants
Low

Grade 3 to 4 diarrhoea · people with metastatic colorectal cancer

The intervention may leads to higher grade 3 to 4 diarrhoea (low certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
OR 2.58 [1.44, 4.64]
5 studies · 2434 participants
Low